-
Evaluating dietary quality and dietary inflammatory potential in cognitive impairment patients in China Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-09 Dongsheng Bian, Furu Liang, Yong You, Xianfeng Li, Hua Hu, Huali Wang, Huayan Liu, Lu Shen, Oumei Cheng, Qiumin Qu, Shunliang Xu, Weihong Kuang, Qinying Ma, Xiaoping Pan, Xinyu Zhao, Yang Zhang, Yifeng Du, Ying Xu, Yong'an Sun, Zhengluan Liao, Jintao Wang, Jianping Li, Jinwen Xiao, Haixia Li, Xinyi Xie, Zike Yun, Jieli Geng, Wenwei Cao, Nan Zhi, Rujing Ren, Hengge Xie, Gang Wang
Diet plays a critical role in the prevention and treatment of cognitive impairment, yet dietary intake in patients with cognitive impairment in China remains insufficiently studied.
-
Presynaptic loss and axonal degeneration synergistically correlate with longitudinal neurodegeneration and cognitive decline Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-11 Dai Shi, Chenghui Ye, Anqi Li, Pan Sun, Guoyu Lan, Laihong Zhang, Xin Zhou, Liemin Zhou, Zhen Liu, Tengfei Guo
Baseline and longitudinal characteristics of cerebrospinal fluid (CSF) growth-associated protein 43 (GAP-43) and plasma neurofilament light (NfL) and how they correlate interactively with neurodegeneration and cognitive decline in Alzheimer's disease (AD) are not fully understood.
-
“Real‐world” eligibility for anti‐amyloid treatment in a tertiary memory clinic setting Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-13 Sinthujah Vigneswaran, Everard G. B. Vijverberg, Frederik Barkhof, Elsmarieke van de Giessen, Afina W. Lemstra, Yolande Pijnenburg, Charlotte E. Teunissen, Wiesje M. van der Flier, Argonde C. van Harten
INTRODUCTIONThe societal impact of anti‐amyloid treatment (AAT) for Alzheimer's disease (AD) depends largely on patient eligibility. Estimates suggest that 1% to 18% of individuals with AD may qualify for AAT; however, data from everyday clinical practice remain limited. This study assessed AAT eligibility in patients at a tertiary memory clinic.METHODSWe included 1309 new patients (63 ± 8 years, 45%
-
White matter trajectories in Down syndrome and Alzheimer's disease: Insights from diffusion tensor–based morphometry Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-13 Fedal Saini, Phoebe Ivain, Mina Idris, Jasmine Wells, Leda Bianchi, Miren Tamayo‐Elizalde, Flavio Dell'Acqua, André Strydom
INTRODUCTIONDiffusion magnetic resonance imaging studies investigating Down syndrome (DS) and Alzheimer's disease (AD) have mainly relied on white matter (WM) skeleton‐based techniques, potentially overlooking broader WM architecture.METHODWe applied diffusion tensor–based morphometry (D‐TBM), a novel whole‐volume WM registration technique, to characterize WM properties in DS. Between‐ and within‐group
-
A multidomain trial for cognition in women with cardiovascular disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-13 Shannon Halloway, Michael E. Schoeny, Zoe Arvanitakis, Annabelle Santos Volgman, Susan J. Pressler, Sachin Vispute, Kaitlin Wilhelm, Jeffrey A. Borgia, JoEllen Wilbur, Lisa L. Barnes
INTRODUCTIONWe evaluated the independent and combined efficacies of MindMoves (24‐week physical activity and cognitive training) on cognition and serum neurotrophic biomarkers in older women with cardiovascular disease (CVD).METHODSThis 2 × 2 factorial design randomized controlled trial (NCT04556305) tested efficacies of Mind (cognitive training) and Move (lifestyle physical activity) on change in
-
Ultra‐fast MRI for dementia diagnosis and treatment eligibility: A prospective study Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Miguel Rosa‐Grilo, Haroon R. Chughtai, David L. Thomas, Daniel C. Alexander, Millie Beament, Christopher R. S. Belder, H. Rolf Jäger, Emma A. Lim, Nicholas Magill, Dermot Mallon, Jennifer M. Nicholas, Owen Nicholas, Floey Urban, Geoff J. M. Parker, Frederik Barkhof, Catherine J. Mummery, Nick C. Fox
INTRODUCTIONMagnetic resonance imaging (MRI) is crucial for dementia diagnosis and a pre‐requisite for amyloid‐lowering therapies in Alzheimer's disease. Despite guidelines, many patients never undergo MRI due to limited scanner availability. Shorter scan times would reduce costs and patient burden. We developed and tested a fast MRI protocol incorporating highly accelerated sequences.METHODSWe compared
-
Disease‐specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Marta Fructuoso, Yannick Vermeiren, Susana Boluda, Lev Stimmer, René A. J. Crans, Laura Xicota, Uli Eisel, Natalia Orti Casan, Philippe Bun, Charles Duyckaerts, Jean‐Maurice Delabar, Andre Strydom, Debby Van Dam, Mara Dierssen, Peter De Deyn, Marie‐Claude Potier
INTRODUCTIONThe locus coeruleus (LC), the brain's primary source of noradrenaline (NA), undergoes early neurodegeneration in Parkinson's disease (PD), Alzheimer's diseases (AD), and Down syndrome (DS); however, differences have not been examined in parallel.METHODSPost mortem brains (n = 67) from individuals with AD, DS‐AD, and PD without and with dementia (PD‐D) and controls were analyzed for amyloid
-
Correction to “Cultural‐centered approaches to adapt a cognitive assessment tool in indigenous communities from Amazonas: The role of participant‐researcher partnerships” Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12
Souza-Talarico JN, Bezerra CC, Toledo et al. Cultural-centered approaches to adapt a cognitive assessment tool in indigenous communities from Amazonas: the role of participant-researcher partnerships. Alzheimers Dement. 2023;19:e076799. doi: 10.1002/alz.076799 In the list of authors, the name “Vanessa Vasconcellos Duarte” was written incorrectly. The correct name is “Vanessa Vasconcelos Duarte” (with
-
Impact of APOE4‐related dementia risk in underrepresented groups from the All of Us research program Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Valentina Ghisays, Ehsan Khajouei, Ignazio S. Piras, Michael H. Malek‐Ahmadi, Hillary D. Protas, Dhruman D. Goradia, Yinghua Chen, Marcus Naymik, Donald Saner, Olivia J. Veatch, Clayton O. Mansel, Yi Su, Matthew J. Huentelman, Jason H. Karnes, Eric M. Reiman
INTRODUCTIONLongitudinal electronic health records (EHRs), “dementia” diagnostic codes, and genetic data from All of Us were used to see if there is a higher risk of dementia and an attenuated impact of apolipoprotein ε4 (APOE4) on Alzheimer's disease (AD) risk in Black and Hispanic/Latino groups.METHODSParticipants included 9,784 Hispanic/Latinos, 14,937 Non‐Hispanic Blacks (NHB), and 60,388 Non‐Hispanic
-
Associations between temporal lobe cortical NODDI measures and memory function in individuals without clinical dementia Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Jay J. Pillai, Robert I. Reid, Stephen D. Weigand, Petrice M. Cogswell, Prashanthi Vemuri, Mary M. Machulda, David S. Knopman, Jonathan Graff‐Radford, Ronald C. Petersen, Clifford R. Jack
INTRODUCTIONTemporal cortical microstructural changes precede cortical atrophy during memory decline. We used neurite orientation dispersion and density imaging (NODDI) to assess such early microstructural change.METHODSCognitively unimpaired (CU, n = 725) and mildly cognitively impaired (MCI, n = 111) participants from the Mayo Clinic Study of Aging underwent 3T magnetic resonance imaging (MRI), including
-
Influence of ethnicity on the diagnostic accuracy of plasma p‐tau217 for the identification of Alzheimer's disease: A consecutive mixed memory clinic cohort study Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Daniel Kjaergaard, T. Rune Nielsen, Erik Stomrud, Sebastian Palmqvist, Divya Bali, Anna Orduña Dolado, Shorena Janelidze, Oskar Hansson, Gunhild Waldemar, Anja Hviid Simonsen
INTRODUCTIONBlood‐based biomarkers have demonstrated high accuracy for identifying Alzheimer's disease (AD) pathology. However, the lack of representative cohorts creates a knowledge gap regarding their real‐world applicability. We examined the influence of ethnicity on the diagnostic accuracy of plasma tau phosphorylated at threonine 217 (p‐tau217) in identifying AD.METHODSA total of 1170 mixed memory
-
Gut dysbiosis in Down syndrome: A potentially unexplored culprit for early Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Herminia Diana Rosas, Xochitl C. Morgan, Yiran Tao, Florence Lai, Nathaniel D. Mercaldo
INTRODUCTIONGut dysbiosis has been found to play a role in sporadic Alzheimer's disease (AD) but has not been explored in Down syndrome (DS), despite the strong relationship between DS and early AD. Here, we compared the gut microbiomes of 20 adults with DS, either cognitively stable or with mild cognitive impairment.METHODSDNA from stool samples was profiled using 16S rRNA sequencing.RESULTSCognitive
-
Perceptual discrimination of complex objects: Apolipoprotein E e4 gene‐dose effects in mid‐life Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Claire Lancaster, Sam Berens, Jessica Daly, Jennifer Rusted, Chris M. Bird
INTRODUCTIONComplex perceptual discrimination is supported by tau‐vulnerable regions of the medial temporal lobe (MTL); notably the perirhinal cortex. This research tests whether there is a gene‐dose effect of apolipoprotein E (APOE) e4 on perceptual discrimination in mid‐life.METHODSThree hundred and thirteen adults (45–65 years; grouped by APOE e4 gene‐dose (142 APOE33, 135 APOE34, 36 APOE44)) completed
-
Integrating plasma p‐tau217 and digital cognitive assessments for early detection in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Casey R. Vanderlip, Craig E. L. Stark
INTRODUCTIONPlasma phosphorylated tau (p‐tau)217 is an early Alzheimer's disease (AD) biomarker, but the timing of pathological changes and cognitive decline varies substantially. Digital cognitive assessments can detect subtle cognitive changes, suggesting they may complement p‐tau217 for early detection. Here, we evaluate whether combining these tools improves the detection of individuals at risk
-
Cerebrospinal fluid and brain positron emission tomography measures of synaptic vesicle glycoprotein 2A: Biomarkers of synaptic density in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Adam P. Mecca, Nicholas J. Ashton, Ming‐Kai Chen, Ryan S. O'Dell, Takaya Toyonaga, Wenzhen Zhao, Juan J. Young, Elaheh Salardini, Kara A. Bates, Jocelyn Ra, Sam Goodcase, Jason A. Silva‐Rudberg, Nabeel B. Nabulsi, Ann Brinkmalm, Hlin Kvartsberg, Michael Schöll, Johanna Nilsson, Amy F. T. Arnsten, Yiyun Huang, Oskar Hansson, Henrik Zetterberg, Richard E. Carson, Kaj Blennow, Christopher H. van Dyck
INTRODUCTIONPositron emission tomography (PET) imaging with ligands for synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising methodology for measuring synaptic density in Alzheimer's disease (AD). We investigated associations between SV2A concentrations in the brain and cerebrospinal fluid (CSF).METHODSTwenty‐one participants with early AD and 7 cognitively normal (CN) individuals underwent
-
Biofluid‐based biomarker panels toward personalized medicine in dementia diagnostics Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Henrik Zetterberg
Alzheimer's & Dementia publishes a set of papers exploring the diagnostic and prognostic capabilities of a novel cutting‐edge multiplexed biomarker measurement technology across neurodegenerative dementias.
-
Arteriolar degeneration and stiffness in cerebral amyloid angiopathy are linked to Aβ deposition and lysyl oxidase Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Lissa Ventura‐Antunes, Alex Nackenoff, Wilber Romero‐Fernandez, Yongchao Wang, Allison M. Bosworth, Alex Prusky, Emmeline Wang, Cristian Carvajal‐Tapia, Alena Shostak, Hannah Harmsen, Bret Mobley, Jose Maldonado, Neely Womble, Elena Solopova, J. Caleb Snider, W. David Merryman, Ethan S. Lippmann, Matthew Schrag
INTRODUCTIONThe morphological and molecular changes associated with the degeneration of arterioles in cerebral amyloid angiopathy (CAA) are incompletely understood.METHODSPost mortem brains from 26 patients with CAA or neurological controls were analyzed using light‐sheet microscopy, and morphological features of microvascular degeneration were quantified using surface volume rendering. Vascular stiffness
-
A lifespan perspective on cognitive reserve and risk for dementia Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 William S. Kremen, Malin Ericsson, Margaret Gatz, Ida K. Karlsson, Marianne Nygaard, Nancy L. Pedersen, Matthew S. Panizzon
INTRODUCTIONWe addressed whether higher education plays a causal role in reducing dementia risk by comparing two indices of cognitive reserve: education and young adult general cognitive ability (GCA).METHODSWe conducted a 52‐year survival analysis to examine associations of GCA and education with dementia in 16,619 male conscripts identified in Swedish national health registries born between 1936
-
Alzheimer's disease plasma biomarkers in the Midwestern Amish Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Ping Wang, Yeunjoo E. Song, Audrey Lynn, Kristy Miskimen, Alex Gulyayev, Michael B. Prough, Daniel A. Dorfsman, Renee A. Laux, Sarada L. Fuzzell, Sherri D. Hochstetler, Andrew F. Zaman, Larry D. Adams, Laura J. Caywood, Jason E. Clouse, Sharlene D. Herington, Patrice Whitehead, Yining Liu, Noel Moore, Paula Ogrocki, Alan J. Lerner, Anthony J. Griswold, Jeffery M. Vance, Michael L. Cuccaro, William
INTRODUCTIONAlzheimer's disease (AD) plasma biomarkers are non‐invasive measures of the key amyloid beta (Aβ) and tau pathologies. Validation and generalization studies are needed to fully understand their potential for AD prediction and diagnosis in the elderly population.METHODSIn 1067 Amish individuals aged ≥ 65, we measured plasma Aβ and tau to assess their relationships with AD‐related outcomes
-
Cell‐specific protein expression in Alzheimer's disease prefrontal cortex Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Maryam Gholampour, Malay K. Basu, Russell H. Swerdlow, Xinming Zhuo, Mohammad Haeri
INTRODUCTIONAnalyzing the proteomes of different brain cell types is fundamental for understanding the pathophysiology of Alzheimer's disease (AD). However, spatial analysis of these diverse and limited cell populations poses significant challenges.METHODSThe GeoMx Digital Spatial Profiler (DSP) platform was used to analyze protein level in the prefrontal cortex of AD and non‐AD brains. The platform
-
Assessing the Global Impact of Brain Small Vessel Disease on Cognition: The Multi‐Ethnic Study of Atherosclerosis Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-12 Sokratis Charisis, Tanweer Rashid, Christina Dintica, Mitzi Gonzales, Hangfan Liu, Jeffrey B. Ware, Thomas R. Austin, Paul N. Jensen, Alison E. Fohner, Jordan E. Tanley, Jingzhong Ding, José A. Luchsinger, Bonnie Sachs, Ilya M. Nasrallah, R. Nick Bryan, Kathleen M. Hayden, David Wolk, Katya Rascovsky, Christos Davatzikos, William T. Longstreth, Kristine Yaffe, Sudha Seshadri, Susan R. Heckbert, Timothy
INTRODUCTIONWe aimed to examine the global impact of brain small vessel disease (SVD) on cognitive performance.METHODSIn 892 participants from the Multi‐Ethnic Study of Atherosclerosis (MESA), we derived perivascular spaces (PVS), white matter hyperintensities (WMH), microbleeds (MB), and white matter fractional anisotropy (FA) and trace (TR). Cognitive function was assessed with a comprehensive neuropsychological
-
GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-11 Selina M. Vattathil, Freida Blostein, Tyne W. Miller-Fleming, Lea K. Davis, , , Thomas S. Wingo, Aliza P. Wingo
Neuropsychiatric symptoms in dementia (NPS) collectively refer to behavioral and psychological symptoms affecting individuals with mild cognitive impairment (MCI) or Alzheimer's disease or related dementia (ADRD). NPS are among the most troubling aspects of living with dementia but their treatments have limited efficacy. We aim to investigate genetic variants contributing to NPS to identify new therapeutic
-
Associations between Aβ deposition and neurometabolic alterations in Alzheimer's disease: Insights from hybrid 3D MRSI‐PET imaging Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-11 Miao Zhang, Jialin Hu, Yaoyu Zhang, Ziyu Meng, Yibo Zhao, Yudu Li, Wen Jin, Xiao‐Hang Qian, Lijun Wang, Guanyu Ye, Xu‐Feng Jiang, Ya‐Dong Li, Jian Ye, Huidong Tang, Jun Liu, Parashkev Nachev, Zhi‐Pei Liang, Biao Li, Yao Li
INTRODUCTIONUnderstanding the neurometabolic changes associated with amyloid‐β (Aβ) deposition is important for early Alzheimer's disease (AD) diagnosis, but their spatial relationships remained unexplored due to technical limitations.METHODSWe investigated the relationship between Aβ deposition and neuronal and glial metabolites using high‐resolution 3D magnetic resonance spectroscopic imaging (MRSI)
-
Correction to “TRIM25 mutation (p.C168*), coding for an E3 ubiquitin ligase, is a cause of early‐onset autosomal dominant dementia with amyloid load and Parkinsonism.” Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-11
Gómez-Tortosa E, Baradaran-Heravi Y, Dillen L, et al. TRIM25 mutation (p.C168*), coding for an E3 ubiquitin ligase, is a cause of early-onset autosomal dominant dementia with amyloid load and Parkinsonism. Alzheimers Dement. 2023; 19: 2805-2815. doi: 10.1002/alz.12913 In the Funding information section, the text “Instituto de Salud Carlos III, Grant/Award Numbers: PI14/00099, PI20/00469” was incorrect
-
Epigenome‐wide association study of cerebrospinal fluid–based biomarkers of Alzheimer's disease in cognitively normal individuals Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-11 Anke Hüls, Jiaqi Liu, Chaini Konwar, Karen N. Conneely, Allan I. Levey, James J. Lah, Aliza P. Wingo, Thomas S. Wingo
INTRODUCTIONCerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are reliable predictors of future AD risk. We investigated whether pre‐clinical changes in AD CSF biomarkers are reflected in blood DNA methylation (DNAm) levels in cognitively normal participants.METHODSWe profiled blood‐based DNAm with the EPIC array in participants without a diagnosis of cognitive impairment in the Emory
-
Reply to “Vascular small fiber neuropathy in neuronal intranuclear inclusion disease” Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-10 Minglei Liu, Yuming Xu, Jing Yang
-
Correction to “Cognitive impairment and COVID‐19 in an urban indigenous community from Amazonas” Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-10
-
Vascular small fiber neuropathy in neuronal intranuclear inclusion disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-10 Yihang Han, Yanjuan Wang, Yujia Cao, Jian Xie, Yunnan Lu, Huixia Lin, Di Wu, Zhijun Zhang
Dear Editor, We were interested in the recent study by Liu et al., which analyzed cutaneous small nerve fibers of participants with neuronal intranuclear inclusion disease (NIID), Parkinson's disease (PD), Alzheimer's disease (AD), and diabetic peripheral neuropathy (DPN). Their findings revealed widespread and severe small fiber neuropathy (SFN) in NIID, characterized by a non-length-dependent reduction
-
Diverse tau pathologies in late‐life mood disorders revealed by PET and autopsy assays Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-09 Shin Kurose, Sho Moriguchi, Manabu Kubota, Kenji Tagai, Yuki Momota, Masanori Ichihashi, Yasunori Sano, Hironobu Endo, Kosei Hirata, Yuko Kataoka, Ryoji Goto, Yuki Mashima, Yasuharu Yamamoto, Hisaomi Suzuki, Shinichiro Nakajima, Masashi Mizutani, Terunori Sano, Kazunori Kawamura, Ming‐Rong Zhang, Harutsugu Tatebe, Takahiko Tokuda, Mitsumoto Onaya, Masaru Mimura, Naruhiko Sahara, Hidehiko Takahashi
INTRODUCTIONLate‐life mood disorders (LLMDs) may represent prodromal manifestations of neurodegenerative dementia; however, the neuropathological basis of LLMDs, including depression and bipolar disorder, remains unclear. We aimed to investigate the involvement of Alzheimer's disease (AD) and non‐AD tau pathologies in LLMD participants.METHODSFifty‐two LLMD participants and 47 age‐ and sex‐matched
-
Correction to “Using remote, digital, multi‐day testing to characterize long‐term forgetting in cognitively unimpaired older adults” Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-07
Molinare CP, Soberanes D, Dubbelman M, et al. Using remote, digital, multi-day testing to characterize long-term forgetting in cognitively unimpaired older adults. Alzheimers Dement. 2025; 21:e70047. doi: 10.1002/alz.70047 The third affiliation should read: 3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 149 13th St, Boston, MA 02129, USA The affiliation that is
-
Diagnostic performance of plasma p‐tau217 and Aβ42/40 biomarkers in the outpatient memory clinic Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-06 Yoav D. Piura, Daniel J. Figdore, Christian Lachner, Joshua Bornhorst, Alicia Algeciras‐Schimnich, Neill R. Graff‐Radford, Gregory S. Day
INTRODUCTIONPlasma biomarkers of Alzheimer's disease (AD) represent accessible alternatives to positron emission tomography (PET) and cerebrospinal fluid (CSF)‐based biomarkers in well‐characterized cohorts. It remains to be determined whether performance is maintained in outpatient clinics comprised of patients with multiple causes of cognitive impairment.METHODSPlasma phosphorylated tau217 (p‐tau217)
-
Issue Information Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-06
Click on the article title to read more.
-
Association of Alzheimer's disease concerns with amyloid burden and lifestyle behaviors in cognitively unimpaired older adults Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-06 Francesca R. Farina, Marc Bennett, Joshua D. Grill, Reisa Sperling, Brian Lawlor, James W. Griffith
INTRODUCTIONThe extent to which Alzheimer's disease (AD) concerns relate to pathological changes in cognitively unimpaired populations is unclear.METHODSWe analyzed screening data from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's (A4) study to determine if AD concerns are associated with amyloid burden in cognitively unimpaired older adults, and how they relate to lifestyle. AD concerns were
-
Lipoprotein(a) levels in Down syndrome: A conundrum Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-06 Herminia Diana Rosas, Florence Lai, Nathaniel Mercaldo
INTRODUCTIONLipoprotein a (Lp(a)) is a low‐density lipoprotein (LDL)‐like particle that has been associated with risk for vascular inflammation, atherogenesis, calcification, and thrombosis in the general population but is also a risk factor for Alzheimer disease (AD).OBJECTIVEThe aim of this study was to conduct a retrospective study of lipoprotein a, Lp(a), levels in adults with Down syndrome (DS)
-
The history of Down syndrome–associated Alzheimer's disease; past, present, and future Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-05 Lucia Maure-Blesa, María Carmona-Iragui, Ira Lott, Elizabeth Head, Thomas Wisniewski, Michael S. Rafii, Joaquín Espinosa, Jesús Flórez, William C. Mobley, Anthony Holland, André Strydom, Shahid Zaman, Juan Fortea
The landscape of Down syndrome–associated Alzheimer's disease (DSAD) research reflects decades of scientific endeavor and collaborative effort, charting a remarkable journey from initial observations to the elucidation of complex genetic and molecular mechanisms. This perspective article chronicles key milestones and breakthroughs, paying homage to the pioneering scientists and advancements that have
-
Participant perspectives on online interventions for diverse caregivers of persons living with dementia Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-05 Concepción Barrio, Jiaming Liang, Yvette I. Cordero, María P. Aranda
INTRODUCTIONThe evidentiary base for dementia caregiver programs is still emerging and is less clear for diverse racial and ethnic minoritized populations. We explored in‐depth perspectives about program participation, acceptability, and recommendations from diverse caregivers who completed one of three versions of the Savvy Caregiver Program.METHODSWe conducted 19 focus groups with 92 caregivers who
-
LC‐MS/MS proteomics identifies plasma proteins related to cognition over 9‐year follow‐up Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-05 Hailey A. Adegboye, Khiry L. Patterson, Julia Libby, Yunyi Sun, Panpan Zhang, Dandan Liu, W. Hudson Robb, Amalia J. Peterson, Keith R. Cole, Albert B. Arul, Nekesa C. Oliver, Marsalas D. Whitaker, Kimberly R. Pechman, Logan Dumitrescu, Corey J. Bolton, Kaj Blennow, Henrik Zetterberg, Timothy J. Hohman, Renã A. S. Robinson, Angela L. Jefferson
INTRODUCTIONThis project identified plasma proteins predictive of cognitive decline across a robust neuropsychological protocol over a 9‐year period.METHODSVanderbilt Memory and Aging Project participants (n = 336, 73 ± 7 years, 59% male, 87% non‐Hispanic White, 10% Black/African American) underwent blood draw for baseline plasma protein abundance using mass spectrometry analysis of tandem mass tag
-
Tau phosphorylation at Alzheimer's disease biomarker sites impairs its cleavage by lysosomal proteases Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-05 Courtney Lane‐Donovan, Andrew W. Smith, Rowan Saloner, Bruce L. Miller, Kaitlin B. Casaletto, Aimee W. Kao
INTRODUCTIONPhospho‐tau peptides from the proline‐rich domain (PRD) of tau are sensitive biomarkers for Alzheimer's disease (AD). The PRD is known to be relatively resistant to lysosomal proteolytic cleavage, but the effects of phosphorylation on cleavage are unknown.METHODSUsing in silico modeling and in vitro protease assays, we quantified the effects of phosphorylation on lysosomal proteolysis of
-
Correction to “Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: Results of the CoSCo study” Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-05
Hong YJ, Choi SH, Kim SY, et al. Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: Results of the CoSCo study. Alzheimers Dement. 2025;21:e14473. doi:10.1002/alz.14473 In the published article, the graphs for Figure 3 and 4 were mistakenly swapped. The graph intended for Figure 3 was placed in Figure 4, and vice versa. However, the citations
-
-
Retinal optical coherence tomography angiography imaging in population studies for study of microvascular dysfunction in Alzheimer's disease and related dementias Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-02 Amir H. Kashani, Tos T. J. M. Berendschot, Sophie Bonnin, Lucia Sobrin, Danilo Andrade De Jesus, Luisa Sanchez Brea, Ana Collazo Martinez, Rajiv Raman, Victor A. de Vries, Haifan Huang, , , , , , Tom MacGillivray, Wishal D. Ramdas, Frank C. T. van der Heide
Widespread use of retinal optical coherence tomography angiography (OCT-A) imaging requires methodological and analytical consensus to ensure reproducible and accurate results in epidemiological studies on Alzheimer's disease and related dementias (ADRD).
-
Common driving behaviors in older adults with dementia: Insights from a systematic literature review Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-04 Ranuki Onara Hettiarachchige, Mark J. Rapoport, Gary Naglie, Evelyn Vingilis, Jane Seeley, Shahab Alizadeh, Sayeh Bayat
Dementia impairs driving skills, but the specific driving behaviors affected are not fully understood. This project reviewed the literature on driving behaviors more common among people with dementia compared to age‐matched healthy controls. A search of Scopus, Medline All, and Embase databases (1994 to September 2024) identified relevant studies. Articles were included if they addressed driving behaviors
-
Examining the association between synaptic density and neurofibrillary tau among cognitively impaired and unimpaired older adults with and without Alzheimer's disease pathology Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-04 Alexandra H. DiFilippo, Erin M. Jonaitis, Gilda E. Ennis, Andrew K. McVea, Max McLachlan, Brecca Bettcher, Nicholas Schulz, Mary‐Elizabeth Pasquesi, Nancy J. Davenport‐Sis, Yer Thor, Ethan Grover, Nathaniel Chin, Todd E. Barnhart, Sanjay Asthana, Tobey J. Betthauser, Jonathan W. Engle, Sterling C. Johnson, Barbara B. Bendlin, Bradley T. Christian
INTRODUCTIONSynapse loss is a key driver of cognitive decline in Alzheimer's disease (AD), yet its direct relationship with neurofibrillary tau tangle (NFT) burden remains unclear. This study leveraged positron emission tomography (PET) imaging to investigate the link between NFT accumulation and synaptic density in older adults with and without AD pathology.METHODSOlder adults (N = 94) underwent PET
-
Acute experimental colitis in 5xFAD Alzheimer's disease mice leads to enhanced monocyte infiltration into the brain accompanied by reduced β‐amyloid deposition Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-03 Nanda K. Navalpur Shanmugam, Frank Zamudio, Deepak K. Vijaya Kumar, Kianna A. Barrett, Ryan VanDoren, Meng Chen, Olivia M. Barr, Sara Watson, Chih‐Chung Jerry Lin, William A. Eimer, Mehdi Jorfi, Se Hoon Choi, Robert D. Moir, Rudolph E. Tanzi
INTRODUCTIONEmerging evidence has connected Alzheimer's disease (AD) to systemic inflammation, intestinal abnormalities, and altered gut microbiota, highlighting the significance of the gut–brain axis. Here, we investigated the impact of acute experimental colitis (acute colitis) on AD pathology.METHODSAcute colitis was induced in 2‐month‐old 5xFAD mice using dextran sodium sulfate (DSS) to assess
-
Detection of emergency department patients at risk of dementia through artificial intelligence Alzheimers Dement. (IF 13.0) Pub Date : 2025-06-03 Inessa Cohen, Richard Andrew Taylor, Haipeng Xue, Isaac V. Faustino, Natalia Festa, Cynthia Brandt, Emily Gao, Ling Han, Siddarth Khasnavis, James M. Lai, Adam P. Mecca, Atharva Vinay Sapre, Juan Young, Michael Zanchelli, Ula Hwang
INTRODUCTIONThe study aimed to develop and validate the Emergency Department Dementia Algorithm (EDDA) to detect dementia among older adults (65+) and support clinical decision‐making in the emergency department (ED).METHODSIn a multisite retrospective study of 759,665 ED visits, electronic health record data from Yale New Haven Health (2014–2022) were used to train three supervised and semi‐unsupervised
-
Response to “Comment on ‘Independent associations of high‐density lipoprotein cholesterol and triglyceride levels with Alzheimer's disease and related dementias’ ” Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-31 Erin L. Ferguson, Thomas J. Hoffmann, Akinyemi Oni‐Orisan, Neil Risch, Ronald M. Krauss, Catherine A. Schaefer, Maria Glymour
-
-
Heterogeneous treatment effects of GLP‐1RAs and SGLT2is on risk of Alzheimer's disease and related dementia in patients with type 2 diabetes: Insights from a real‐world target trial emulation Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-31 Huilin Tang, William T. Donahoo, Steven T. DeKosky, Yao An Lee, Pareeta Kotecha, Mikael Svensson, Jiang Bian, Jingchuan Guo
INTRODUCTIONThis study assessed the heterogeneous treatment effects (HTEs) of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) on the risk of Alzheimer's disease and related dementias (ADRD).METHODSThis target trial emulation study included adults (≥ 50 years) with type 2 diabetes (T2D) and newly prescribed a GLP‐1RA, SGLT2i, or other second‐line
-
Caregiving at end‐of‐life: How do family structure and dementia status impact antidepressant and anxiolytic prescriptions among families? Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-31 Eli Iacob, Mike Hollingshaus, Rebecca L. Utz, Djin L. Tay, Katherine A. Ornstein, Rachael Alexander, Pamela Barrientos, Lee Ellington, Mike Newman, Tom Belnap, Amy M. Cizik, Ken R. Smith, Huong D. Meeks, Caroline E. Stephens
INTRODUCTIONEnd‐of‐life (EOL) caregiving is associated with stress and burden, especially for persons with dementia. Little is known, however, about how dementia diagnosis, family structure, and co‐residence influence the prevalence of antidepressants and anxiolytics (psychiatric prescriptions) among spouses and adult children during EOL caregiving.METHODSThis was a retrospective cohort study of spouses
-
Social determinants of health and their impact on depression in family caregivers of those with dementia: The importance of intermediary determinants Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-31 Hannah Cho, Yeji Hwang
INTRODUCTIONDementia family caregivers face a significant burden due to the progressive nature of the disease, which places them at high risk for depression. Because a lack of information is available on the social determinants of health that impact depression, this study investigated this relationship.METHODSThis study was a secondary data analysis using the 2017 National Health and Aging Trends Study
-
Dual defense: Opportunities and challenges of GLP‐1 receptor agonists in reducing dementia risk in type 2 diabetes! Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-30 Saman Adnan, Muniza Qureshi, Sania Arif, Kinza Fatima
-
Feasibility of lifestyle interventions for cognition in adults with low education Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-30 Daniel O. Clark, Huiping Xu, Christy C. Tangney, Annie W. Lin, Shannon L. Risacher, Andrew J. Saykin, Robert V. Considine, Holly J. Garringer, Lyndsi Moser, Amy Carter, Catherine M. Miller, Briana Sprague, Christopher M. Callahan, Frederick W. Unverzagt
INTRODUCTIONWe report the feasibility and cognitive outcomes of a stage 1b randomized trial testing 3 months of home‐delivered high polyphenol snacks (e.g., nuts, berries) and online speed of processing training among older adults with 12 or fewer years of education.METHODSOne hundred eighty participants were randomized to polyphenol‐rich snacks and online cognitive training, polyphenol snacks and
-
Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-30 Bjørn‐Eivind Kirsebom, Fernando Gonzalez‐Ortiz, Sinthujah Vigneswaran, Geir Bråthen, Ragnhild Eide Skogseth, Berglind Gísladóttir, Peter Harrison, Jonas Alexander Jarholm, Lene Pålhaugen, Arvid Rongve, Per Selnes, Betty Tjims, Michael Turton, Argonde C. Van Harten, Knut Waterloo, Henrik Zetterberg, Tormod Fladby, Kaj Blennow
INTRODUCTIONHeterogeneity of clinical progression in Alzheimer's disease (AD) complicates the assessment of disease progression and treatment effects in trials. This study evaluates the potential of plasma phosphorylated tau‐217 (p‐tau217) to capture this heterogeneity.METHODSWe used k‐means clustering to analyze cognitive trajectories in amyloid beta –positive (Aβ+) cognitively normal (CN) and mild
-
Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-29 Bess Frost, James B. Rowe, Rufus O. Akinyemi, Jose F. Abisambra, Nicholas J. Ashton, Matthias Brendel, Luc Buée, David Butler, Maria C. Carrillo, Peter Chung, Claire D. Clelland, Sarah L. DeVos, Kristophe Diaz, Rebecca M. Edelmayer, Fanny M. Elahi, Ratnavalli Ellajosyula, Colin Ewen, Igor Camargo Fontana, Marie‐Christine Galas, Oskar Hansson, Günter Höglinger, Kanta Horie, Agustín Ibanez, Linde Jacobs
Recent years have seen major advances in tau‐associated brain disorders through interdisciplinary research spanning molecular biology, neuroimaging, clinical trials, and therapeutic development. The Tau2024 Global Conference, hosted by the Alzheimer's Association, CurePSP, and Rainwater Charitable Foundation, showcased these efforts by bringing together researchers and experts worldwide to discuss
-
Correction to “Effects of a ketogenic and low‐fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer's disease” Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-29
Dilmore AH, Martino C, Neth BJ, et al. Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer's disease. Alzheimer's Dement. 2023;4805-4816. https://doi.org/10.1002/alz.13007 The Conflict of Interest Statement is incomplete. The full Conflict of Interest Statement should be: Rima Kaddurah-Daouk is an inventor of key patents in the field
-
Prediction of longitudinal synaptic loss in Alzheimer's disease using tau PET and plasma biomarkers Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-28 Jie Wang, Qi Huang, Xing Chen, Zhiwen You, Kun He, Xiaoxie Mao, Yiyun Huang, Nicolai Franzmeier, Michael Schöll, Tengfei Guo, Jun Zhao, Yihui Guan, Ruiqing Ni, Binyin Li, Fang Xie
INTRODUCTIONWe investigated the associations of longitudinal synaptic loss and cognitive decline with tau burden and plasma biomarkers in Alzheimer's disease (AD).METHODSTwenty cognitively impaired (CI) individuals and 16 healthy controls (HC) underwent cognitive and plasma biomarker assessments, amyloid positron emission tomography (PET), tau PET, and synaptic density PET; after 1 year, tau and synaptic
-
Sex differences in the confounders influencing the relationships linking socioeconomic factors and cognitive performance with family history of Alzheimer's disease and related dementias Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-27 Jun He, Brenda Cabrera‐Mendoza, Eleni Friligkou, Adam P. Mecca, Christopher H. van Dyck, Gita A. Pathak, Renato Polimanti
INTRODUCTIONLimited information is available regarding sex differences in the relationship of socioeconomic status and cognitive performance with Alzheimer's disease and related dementias (ADRD) family history.METHODSLeveraging the UK Biobank (N = 448,100) and All of Us Research Program (N = 240,319), we conducted observational and genetically informed analyses to test the sex‐specific associations
-
Cognitive assessment tools for Arabic‐speaking older adults: A systematic review Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-27 Mayssan Kabalan, Ola Bazzi, Josleen Al‐Barathie, Ola El Zein, Lara Chehabeddine, Joanne Khabsa, Monique Chaaya, Carlos Mendes de Leon, Martine Elbejjani
This systematic review aims to identify available cognitive assessments for Arabic‐speaking older adults and to assess their validity and performance. A comprehensive search was conducted using Medline, Embase, and APA PsycInfo up to November 2023, encompassing studies validating or using cognitive tools in Arabic for individuals aged ≥ 50. We identified 29 validation studies for 20 cognitive tools
-
Experimental modeling of Alzheimer's disease: Translational lessons from cross‐taxon analyses Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-27 Konstantin B. Yenkoyan, Maria M. Kotova, Kirill V. Apukhtin, David S. Galstyan, Tamara G. Amstislavskaya, Tatyana Strekalova, Murilo S. de Abreu, Vergine A. Chavushyan, Lee Wei Lim, Longen Yang, Denis D. Rosemberg, Allan V. Kalueff
Alzheimer's disease (AD) is a severely debilitating neurodegenerative disease with a rapidly increasing global prevalence, poorly understood causes, and no efficient treatments. Experimental models are valuable for studying AD pathogenesis, including amyloid beta and tau accumulation, synaptic dysfunction, and neuroinflammation. While no model fully reproduces the disease, we take an evolutionary biology
-
Predicting progression from MCI to dementia using cortical disarray measurement from diffusion MRI Alzheimers Dement. (IF 13.0) Pub Date : 2025-05-27 Mario Torso, Pegah Khosropanah, Steven A. Chance, Gerard R. Ridgway
BACKGROUNDThis study evaluates the capability of cortical microstructural measures from diffusion magnetic resonance imaging (MRI) to predict progression from mild cognitive impairment (MCI) to dementia, compared to commonly used macrostructural measures. Identification of high‐risk individuals can support both clinical practice and trials.METHODSStructural and diffusion MRI scans of 826 participants